- Home
- CATO vs GUTS Comparison
CATO vs GUTS Comparison
Compare CATO & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- GUTS
- Stock Information
- Founded
- CATO 1946
- GUTS 2010
- Country
- CATO United States
- GUTS United States
- Employees
- CATO N/A
- GUTS N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- GUTS
- Sector
- CATO Consumer Discretionary
- GUTS
- Exchange
- CATO Nasdaq
- GUTS NYSE
- Market Cap
- CATO 59.2M
- GUTS 58.8M
- IPO Year
- CATO N/A
- GUTS 2024
- Fundamental
- Price
- CATO $2.87
- GUTS $1.64
- Analyst Decision
- CATO
- GUTS Buy
- Analyst Count
- CATO 0
- GUTS 1
- Target Price
- CATO N/A
- GUTS $10.00
- AVG Volume (30 Days)
- CATO 43.0K
- GUTS 939.7K
- Earning Date
- CATO 08-21-2025
- GUTS 08-13-2025
- Dividend Yield
- CATO 6.11%
- GUTS N/A
- EPS Growth
- CATO N/A
- GUTS N/A
- EPS
- CATO N/A
- GUTS N/A
- Revenue
- CATO $642,949,000.00
- GUTS $60,000.00
- Revenue This Year
- CATO N/A
- GUTS N/A
- Revenue Next Year
- CATO N/A
- GUTS N/A
- P/E Ratio
- CATO N/A
- GUTS N/A
- Revenue Growth
- CATO N/A
- GUTS N/A
- 52 Week Low
- CATO $2.19
- GUTS $0.87
- 52 Week High
- CATO $6.70
- GUTS $4.92
- Technical
- Relative Strength Index (RSI)
- CATO 53.03
- GUTS 44.51
- Support Level
- CATO $2.73
- GUTS $1.54
- Resistance Level
- CATO $2.99
- GUTS $1.82
- Average True Range (ATR)
- CATO 0.18
- GUTS 0.17
- MACD
- CATO -0.02
- GUTS -0.06
- Stochastic Oscillator
- CATO 30.14
- GUTS 13.12
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.